475 related articles for article (PubMed ID: 27036297)
1. Naringenin prevents TGF-β1 secretion from breast cancer and suppresses pulmonary metastasis by inhibiting PKC activation.
Zhang F; Dong W; Zeng W; Zhang L; Zhang C; Qiu Y; Wang L; Yin X; Zhang C; Liang W
Breast Cancer Res; 2016 Apr; 18(1):38. PubMed ID: 27036297
[TBL] [Abstract][Full Text] [Related]
2. Naringenin: a potential immunomodulator for inhibiting lung fibrosis and metastasis.
Du G; Jin L; Han X; Song Z; Zhang H; Liang W
Cancer Res; 2009 Apr; 69(7):3205-12. PubMed ID: 19318568
[TBL] [Abstract][Full Text] [Related]
3. PKC-ζ mediated reduction of the extracellular vesicles-associated TGF-β1 overcomes radiotherapy resistance in breast cancer.
Zhang F; Zheng Z; Wang L; Zeng W; Wei W; Zhang C; Zhao Z; Liang W
Breast Cancer Res; 2023 Apr; 25(1):38. PubMed ID: 37029374
[TBL] [Abstract][Full Text] [Related]
4. The Marine-Derived Oligosaccharide Sulfate MS80, a Novel Transforming Growth Factor β1 Inhibitor, Reverses Epithelial Mesenchymal Transition Induced by Transforming Growth Factor-β1 and Suppresses Tumor Metastasis.
Zhou J; You W; Sun G; Li Y; Chen B; Ai J; Jiang H
J Pharmacol Exp Ther; 2016 Oct; 359(1):54-61. PubMed ID: 27432893
[TBL] [Abstract][Full Text] [Related]
5. Using adenovirus armed short hairpin RNA targeting transforming growth factor β1 inhibits melanoma growth and metastasis in an ex vivo animal model.
Tai KF; Wang CH
Ann Plast Surg; 2013 Dec; 71 Suppl 1():S75-81. PubMed ID: 24284745
[TBL] [Abstract][Full Text] [Related]
6. Silencing of transforming growth factor-beta1 in situ by RNA interference for breast cancer: implications for proliferation and migration in vitro and metastasis in vivo.
Moore LD; Isayeva T; Siegal GP; Ponnazhagan S
Clin Cancer Res; 2008 Aug; 14(15):4961-70. PubMed ID: 18676771
[TBL] [Abstract][Full Text] [Related]
7. Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads signaling pathway mediated Snail/E-cadherin expression.
Ji Q; Liu X; Han Z; Zhou L; Sui H; Yan L; Jiang H; Ren J; Cai J; Li Q
BMC Cancer; 2015 Mar; 15():97. PubMed ID: 25884904
[TBL] [Abstract][Full Text] [Related]
8. Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-β1 signaling pathway.
Kim S; Lee J; Jeon M; Lee JE; Nam SJ
Oncotarget; 2016 Jan; 7(2):1544-58. PubMed ID: 26637807
[TBL] [Abstract][Full Text] [Related]
9. TGF-β1 secreted by Tregs in lymph nodes promotes breast cancer malignancy via up-regulation of IL-17RB.
Huang SC; Wei PC; Hwang-Verslues WW; Kuo WH; Jeng YM; Hu CM; Shew JY; Huang CS; Chang KJ; Lee EY; Lee WH
EMBO Mol Med; 2017 Dec; 9(12):1660-1680. PubMed ID: 28993429
[TBL] [Abstract][Full Text] [Related]
10. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases.
Muraoka RS; Dumont N; Ritter CA; Dugger TC; Brantley DM; Chen J; Easterly E; Roebuck LR; Ryan S; Gotwals PJ; Koteliansky V; Arteaga CL
J Clin Invest; 2002 Jun; 109(12):1551-9. PubMed ID: 12070302
[TBL] [Abstract][Full Text] [Related]
11. Targeted inactivation of β1 integrin induces β3 integrin switching, which drives breast cancer metastasis by TGF-β.
Parvani JG; Galliher-Beckley AJ; Schiemann BJ; Schiemann WP
Mol Biol Cell; 2013 Nov; 24(21):3449-59. PubMed ID: 24006485
[TBL] [Abstract][Full Text] [Related]
12. SRT1720, a SIRT1 activator, promotes tumor cell migration, and lung metastasis of breast cancer in mice.
Suzuki K; Hayashi R; Ichikawa T; Imanishi S; Yamada T; Inomata M; Miwa T; Matsui S; Usui I; Urakaze M; Matsuya Y; Ogawa H; Sakurai H; Saiki I; Tobe K
Oncol Rep; 2012 Jun; 27(6):1726-32. PubMed ID: 22470132
[TBL] [Abstract][Full Text] [Related]
13. Transforming growth factor-beta1 regulation of ATF-3 and identification of ATF-3 target genes in breast cancer cells.
Kwok S; Rittling SR; Partridge NC; Benson CS; Thiyagaraj M; Srinivasan N; Selvamurugan N
J Cell Biochem; 2009 Oct; 108(2):408-14. PubMed ID: 19582787
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of FGFR signaling by PD173074 improves antitumor immunity and impairs breast cancer metastasis.
Ye T; Wei X; Yin T; Xia Y; Li D; Shao B; Song X; He S; Luo M; Gao X; He Z; Luo C; Xiong Y; Wang N; Zeng J; Zhao L; Shen G; Xie Y; Yu L; Wei Y
Breast Cancer Res Treat; 2014 Feb; 143(3):435-46. PubMed ID: 24398778
[TBL] [Abstract][Full Text] [Related]
15. Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of transforming growth factor beta in a mouse model of breast cancer.
Nam JS; Suchar AM; Kang MJ; Stuelten CH; Tang B; Michalowska AM; Fisher LW; Fedarko NS; Jain A; Pinkas J; Lonning S; Wakefield LM
Cancer Res; 2006 Jun; 66(12):6327-35. PubMed ID: 16778210
[TBL] [Abstract][Full Text] [Related]
16. Modeling and integral X-ray, optical, and MRI visualization of multiorgan metastases of orthotopic 4T1 breast carcinoma in BALB/c mice.
Baklaushev VP; Grinenko NF; Yusubalieva GM; Abakumov MA; Gubskii IL; Cherepanov SA; Kashparov IA; Burenkov MS; Rabinovich EZ; Ivanova NV; Antonova OM; Chekhonin VP
Bull Exp Biol Med; 2015 Feb; 158(4):581-8. PubMed ID: 25705045
[TBL] [Abstract][Full Text] [Related]
17. Multi-stage inhibition in breast cancer metastasis by orally active triple conjugate, LHTD4 (low molecular weight heparin-taurocholate-tetrameric deoxycholate).
Alam F; Al-Hilal TA; Park J; Choi JU; Mahmud F; Jeong JH; Kim IS; Kim SY; Hwang SR; Byun Y
Biomaterials; 2016 Apr; 86():56-67. PubMed ID: 26890038
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells.
Jovanovic IP; Pejnovic NN; Radosavljevic GD; Pantic JM; Milovanovic MZ; Arsenijevic NN; Lukic ML
Int J Cancer; 2014 Apr; 134(7):1669-82. PubMed ID: 24105680
[TBL] [Abstract][Full Text] [Related]
19. OSM potentiates preintravasation events, increases CTC counts, and promotes breast cancer metastasis to the lung.
Tawara K; Bolin C; Koncinsky J; Kadaba S; Covert H; Sutherland C; Bond L; Kronz J; Garbow JR; Jorcyk CL
Breast Cancer Res; 2018 Jun; 20(1):53. PubMed ID: 29898744
[TBL] [Abstract][Full Text] [Related]
20. An novel inhibitor of TGF-β type I receptor, IN-1130, blocks breast cancer lung metastasis through inhibition of epithelial-mesenchymal transition.
Park CY; Min KN; Son JY; Park SY; Nam JS; Kim DK; Sheen YY
Cancer Lett; 2014 Aug; 351(1):72-80. PubMed ID: 24887560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
